Metabolic and immune consequences of antibiotic related microbiome alterations during first-line tuberculosis treatment in Bamako, Mali
BackgroundIndividuals with a history of tuberculosis (TB) treatment are at a higher risk of experiencing a recurrent episode of the disease. Previous cross-sectional studies identified a connection between dysbiosis (alterations) in the gut microbiota composition and the administration of first-line...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1561459/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850278541636141056 |
|---|---|
| author | Dramane Diallo Shan Sun Anou M. Somboro Anou M. Somboro Bocar Baya Amadou Koné Amadou Koné Bassirou Diarra Bassirou Diarra Mohamed Nantoumé Isaac Koloma Mahamadou Diakite Mahamadou Diakite Jane Holl Almoustapha Issiaka Maiga Moussa Seydi Grant Theron Lifang Hou Anthony Fodor Mamoudou Maiga Mamoudou Maiga |
| author_facet | Dramane Diallo Shan Sun Anou M. Somboro Anou M. Somboro Bocar Baya Amadou Koné Amadou Koné Bassirou Diarra Bassirou Diarra Mohamed Nantoumé Isaac Koloma Mahamadou Diakite Mahamadou Diakite Jane Holl Almoustapha Issiaka Maiga Moussa Seydi Grant Theron Lifang Hou Anthony Fodor Mamoudou Maiga Mamoudou Maiga |
| author_sort | Dramane Diallo |
| collection | DOAJ |
| description | BackgroundIndividuals with a history of tuberculosis (TB) treatment are at a higher risk of experiencing a recurrent episode of the disease. Previous cross-sectional studies identified a connection between dysbiosis (alterations) in the gut microbiota composition and the administration of first-line TB antibiotics. However, these studies have not successfully elucidated this dysbiosis’s resulting metabolic and immune consequences.MethodsIn a longitudinal assessment, we studied the antituberculosis drug-related changes in the gut microbiota’s composition and the resulting functional consequences. Sputum for TB culture, peripheral blood for metabolomics and cytokines analysis, and stool for shotgun metagenomics were collected from TB participants at Month-0, Month-2, Month-6 of treatment, and 9 Months after treatment (Month-15). Healthy controls were sampled at Month-0 and Month-6.FindingsWe found notable differences in gut microbiota between individuals with TB and healthy controls. While gut microbiota tended to resemble healthy controls at the end of TB treatment, significant differences for many taxa persisted up to Month-15. Concurrently, disturbances in plasma metabolites, including tryptophan, tricarboxylic acids, and cytokine levels were observed. Certain fatty acids associated with inflammation pathways negatively correlated with the abundance of several taxa.ConclusionWe observed alterations in the gut microbiota composition and function during treatment and at Month-15. Numerous changes in bacterial taxa abundances and inflammation-linked metabolites did not reverse at Month-15. This study suggests potential influences of anti-TB drugs and the gut microbiome on the disease outcome, response to treatment, and resistance to future TB infections. |
| format | Article |
| id | doaj-art-0324b4d6476546bca3bce963f337c21e |
| institution | OA Journals |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-0324b4d6476546bca3bce963f337c21e2025-08-20T01:49:27ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-05-011610.3389/fimmu.2025.15614591561459Metabolic and immune consequences of antibiotic related microbiome alterations during first-line tuberculosis treatment in Bamako, MaliDramane Diallo0Shan Sun1Anou M. Somboro2Anou M. Somboro3Bocar Baya4Amadou Koné5Amadou Koné6Bassirou Diarra7Bassirou Diarra8Mohamed Nantoumé9Isaac Koloma10Mahamadou Diakite11Mahamadou Diakite12Jane Holl13Almoustapha Issiaka Maiga14Moussa Seydi15Grant Theron16Lifang Hou17Anthony Fodor18Mamoudou Maiga19Mamoudou Maiga20University Clinical Research Center (UCRC), Bamako, MaliDepartment of Bioinformatics and Genomics, University of North Carolina at Charlotte, Charlotte, NC, United StatesAntimicrobial Research Unit, College of Health Sciences, University of KwaZulu-Natal, Durban, South AfricaUniversity of Sciences, Techniques, and Technologies of Bamako (USTTB), Bamako, MaliUniversity Clinical Research Center (UCRC), Bamako, MaliUniversity Clinical Research Center (UCRC), Bamako, MaliUniversity of Sciences, Techniques, and Technologies of Bamako (USTTB), Bamako, MaliUniversity Clinical Research Center (UCRC), Bamako, MaliUniversity of Sciences, Techniques, and Technologies of Bamako (USTTB), Bamako, MaliUniversity Clinical Research Center (UCRC), Bamako, MaliUniversity Clinical Research Center (UCRC), Bamako, MaliUniversity Clinical Research Center (UCRC), Bamako, MaliUniversity of Sciences, Techniques, and Technologies of Bamako (USTTB), Bamako, MaliDepartment of Neurology and Center for Healthcare Delivery Science and Innovation, University of Chicago, Chicago, IL, United StatesUniversity Clinical Research Center (UCRC), Bamako, MaliService des Maladies Infectieuses et Tropicales, Fann University Hospital Center, Dakar, SenegalCentre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis, Stellenbosch University, Cape Town, South AfricaFeinberg School of Medicine, Northwestern University, Chicago, IL, United StatesDepartment of Bioinformatics and Genomics, University of North Carolina at Charlotte, Charlotte, NC, United StatesUniversity of Sciences, Techniques, and Technologies of Bamako (USTTB), Bamako, MaliFeinberg School of Medicine, Northwestern University, Chicago, IL, United StatesBackgroundIndividuals with a history of tuberculosis (TB) treatment are at a higher risk of experiencing a recurrent episode of the disease. Previous cross-sectional studies identified a connection between dysbiosis (alterations) in the gut microbiota composition and the administration of first-line TB antibiotics. However, these studies have not successfully elucidated this dysbiosis’s resulting metabolic and immune consequences.MethodsIn a longitudinal assessment, we studied the antituberculosis drug-related changes in the gut microbiota’s composition and the resulting functional consequences. Sputum for TB culture, peripheral blood for metabolomics and cytokines analysis, and stool for shotgun metagenomics were collected from TB participants at Month-0, Month-2, Month-6 of treatment, and 9 Months after treatment (Month-15). Healthy controls were sampled at Month-0 and Month-6.FindingsWe found notable differences in gut microbiota between individuals with TB and healthy controls. While gut microbiota tended to resemble healthy controls at the end of TB treatment, significant differences for many taxa persisted up to Month-15. Concurrently, disturbances in plasma metabolites, including tryptophan, tricarboxylic acids, and cytokine levels were observed. Certain fatty acids associated with inflammation pathways negatively correlated with the abundance of several taxa.ConclusionWe observed alterations in the gut microbiota composition and function during treatment and at Month-15. Numerous changes in bacterial taxa abundances and inflammation-linked metabolites did not reverse at Month-15. This study suggests potential influences of anti-TB drugs and the gut microbiome on the disease outcome, response to treatment, and resistance to future TB infections.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1561459/fulltuberculosisgut microbiome alterationsmetabolic and immune responsetuberculosis treatmentdysbiosisMali |
| spellingShingle | Dramane Diallo Shan Sun Anou M. Somboro Anou M. Somboro Bocar Baya Amadou Koné Amadou Koné Bassirou Diarra Bassirou Diarra Mohamed Nantoumé Isaac Koloma Mahamadou Diakite Mahamadou Diakite Jane Holl Almoustapha Issiaka Maiga Moussa Seydi Grant Theron Lifang Hou Anthony Fodor Mamoudou Maiga Mamoudou Maiga Metabolic and immune consequences of antibiotic related microbiome alterations during first-line tuberculosis treatment in Bamako, Mali Frontiers in Immunology tuberculosis gut microbiome alterations metabolic and immune response tuberculosis treatment dysbiosis Mali |
| title | Metabolic and immune consequences of antibiotic related microbiome alterations during first-line tuberculosis treatment in Bamako, Mali |
| title_full | Metabolic and immune consequences of antibiotic related microbiome alterations during first-line tuberculosis treatment in Bamako, Mali |
| title_fullStr | Metabolic and immune consequences of antibiotic related microbiome alterations during first-line tuberculosis treatment in Bamako, Mali |
| title_full_unstemmed | Metabolic and immune consequences of antibiotic related microbiome alterations during first-line tuberculosis treatment in Bamako, Mali |
| title_short | Metabolic and immune consequences of antibiotic related microbiome alterations during first-line tuberculosis treatment in Bamako, Mali |
| title_sort | metabolic and immune consequences of antibiotic related microbiome alterations during first line tuberculosis treatment in bamako mali |
| topic | tuberculosis gut microbiome alterations metabolic and immune response tuberculosis treatment dysbiosis Mali |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1561459/full |
| work_keys_str_mv | AT dramanediallo metabolicandimmuneconsequencesofantibioticrelatedmicrobiomealterationsduringfirstlinetuberculosistreatmentinbamakomali AT shansun metabolicandimmuneconsequencesofantibioticrelatedmicrobiomealterationsduringfirstlinetuberculosistreatmentinbamakomali AT anoumsomboro metabolicandimmuneconsequencesofantibioticrelatedmicrobiomealterationsduringfirstlinetuberculosistreatmentinbamakomali AT anoumsomboro metabolicandimmuneconsequencesofantibioticrelatedmicrobiomealterationsduringfirstlinetuberculosistreatmentinbamakomali AT bocarbaya metabolicandimmuneconsequencesofantibioticrelatedmicrobiomealterationsduringfirstlinetuberculosistreatmentinbamakomali AT amadoukone metabolicandimmuneconsequencesofantibioticrelatedmicrobiomealterationsduringfirstlinetuberculosistreatmentinbamakomali AT amadoukone metabolicandimmuneconsequencesofantibioticrelatedmicrobiomealterationsduringfirstlinetuberculosistreatmentinbamakomali AT bassiroudiarra metabolicandimmuneconsequencesofantibioticrelatedmicrobiomealterationsduringfirstlinetuberculosistreatmentinbamakomali AT bassiroudiarra metabolicandimmuneconsequencesofantibioticrelatedmicrobiomealterationsduringfirstlinetuberculosistreatmentinbamakomali AT mohamednantoume metabolicandimmuneconsequencesofantibioticrelatedmicrobiomealterationsduringfirstlinetuberculosistreatmentinbamakomali AT isaackoloma metabolicandimmuneconsequencesofantibioticrelatedmicrobiomealterationsduringfirstlinetuberculosistreatmentinbamakomali AT mahamadoudiakite metabolicandimmuneconsequencesofantibioticrelatedmicrobiomealterationsduringfirstlinetuberculosistreatmentinbamakomali AT mahamadoudiakite metabolicandimmuneconsequencesofantibioticrelatedmicrobiomealterationsduringfirstlinetuberculosistreatmentinbamakomali AT janeholl metabolicandimmuneconsequencesofantibioticrelatedmicrobiomealterationsduringfirstlinetuberculosistreatmentinbamakomali AT almoustaphaissiakamaiga metabolicandimmuneconsequencesofantibioticrelatedmicrobiomealterationsduringfirstlinetuberculosistreatmentinbamakomali AT moussaseydi metabolicandimmuneconsequencesofantibioticrelatedmicrobiomealterationsduringfirstlinetuberculosistreatmentinbamakomali AT granttheron metabolicandimmuneconsequencesofantibioticrelatedmicrobiomealterationsduringfirstlinetuberculosistreatmentinbamakomali AT lifanghou metabolicandimmuneconsequencesofantibioticrelatedmicrobiomealterationsduringfirstlinetuberculosistreatmentinbamakomali AT anthonyfodor metabolicandimmuneconsequencesofantibioticrelatedmicrobiomealterationsduringfirstlinetuberculosistreatmentinbamakomali AT mamoudoumaiga metabolicandimmuneconsequencesofantibioticrelatedmicrobiomealterationsduringfirstlinetuberculosistreatmentinbamakomali AT mamoudoumaiga metabolicandimmuneconsequencesofantibioticrelatedmicrobiomealterationsduringfirstlinetuberculosistreatmentinbamakomali |